Liquidia Corp. (LQDA)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
Research Workspace
Put LQDA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Full year 2026 revenue: FY26 guidance $129.9M vs $130M target.
View ThesisMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 36% in its worst 12-month stretch.
View RiskLQDA's growth relies on the continued success of Yutrepia, which is outperforming expectations. Revenue guidance for FY26 is $129.9M, slightly below the $130M target, indicating a potential issue. The stock trades at 15.4× price-to-sales, significantly above the peer median of 2.9×, suggesting that high growth is already priced in. If LQDA cuts guidance, the stock could face a significant decline, with a 46% miss probability for the next quarter. Peer multiples imply a price about 57% below where it trades. This read is provisional.
Trailing returns as of 2026-09-04. LQDA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering LQDA (as of Sep 2026).
Based on 9 Wall Street analysts offering 12-month price targets for LQDA in the last 4 months.
Continue this research
Compare LQDA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| LQDA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 4 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Compare the value case
Put LQDA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase YUTREPIA sales
Yutrepia sales growth exceeds expectations.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $68.66
The last 12 months of price, then the range of analyst 12-month targets from today’s $68.66.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

Advances: Increase YUTREPIA sales
Yutrepia sales growth exceeds expectations.

Advances: Increase YUTREPIA sales
YUTREPIA sales surge supports growth objective.

Advances: Increase YUTREPIA sales
Targets significant revenue growth from YUTREPIA.

Advances: Increase YUTREPIA sales
YUTREPIA profitability and patent news supports sales growth.
Advances: Increase YUTREPIA sales
Stock hitting all-time high indicates strong market confidence.
CEO stock sale raises concerns about insider confidence.